Abstract
In TITAN and SPARTAN, APA added to continuous androgen deprivation therapy (ADT) improved prostate-specific antigen (PSA) response, radiographic progression-free survival (rPFS), metastasis-free survival (MFS), and overall survival (OS) in pts with metastatic castration-sensitive prostate cancer (mCSPC) and nonmetastatic castration-resistant prostate cancer (nmCRPC). We assessed efficacy and safety of APA in age groups from both studies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
